Nanexa AB (publ) (FRA:40M)

Germany flag Germany · Delayed Price · Currency is EUR
0.142
+0.009 (6.78%)
Last updated: Dec 4, 2025, 8:02 AM CET
-35.25%
Market Cap 27.11M
Revenue (ttm) 2.89M
Net Income (ttm) -3.53M
Shares Out n/a
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 208
Average Volume 10
Open 0.142
Previous Close 0.133
Day's Range 0.142 - 0.142
52-Week Range 0.069 - 0.241
Beta n/a
RSI 53.29
Earnings Date Feb 19, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, ... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2007
Employees 13
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 40M
Full Company Profile

Financial Performance

In 2024, Nanexa AB's revenue was 46.69 million, a decrease of -21.07% compared to the previous year's 59.16 million. Losses were -24.91 million, -67.40% less than in 2023.

Financial numbers in SEK Financial Statements

News

There is no news available yet.